10 years of dedication in ophthalmic gene therapy
Deep understanding in ophthalmic disease and molecular/cellular biology of gene therapy
Choice of indications best-suited for gene therapy
Clinical-driven R&D
10 years of dedication in ophthalmic gene therapy
Deep understanding in ophthalmic disease and molecular/cellular biology of gene therapy
Choice of indications best-suited for gene therapy
Clinical-driven R&D
AAV2 vector already proven for Neuroophthalmological application
Optimal vector design to minimize dosage
Allotopic expression technology to restore function of impaired mitochondira
Intravitreal injection: <30min procedure, minimally invasive
Proprietary formulation to enhance efficacy
Proprietary clinical procedure to reduce ocular immune response